We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+12.99%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$1.12B
AUM Growth
+$199M
Cap. Flow
+$144M
Cap. Flow %
12.84%
Top 10 Hldgs %
31%
Holding
95
New
1
Increased
36
Reduced
12
Closed
13

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$56.1M
2
LLY icon
Eli Lilly
LLY
+$9.29M
3
MDT icon
Medtronic
MDT
+$9.04M
4
CI icon
Cigna
CI
+$7.04M
5
ELV icon
Elevance Health
ELV
+$6.73M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$12.1M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$7.59M
3
BMY icon
Bristol-Myers Squibb
BMY
+$5.42M
4
AIMT
Aimmune Therapeutics
AIMT
+$4.76M
5
OMCL icon
Omnicell
OMCL
+$4.24M

Sector Composition

Rank Sector Weight
1 Healthcare 94.2%
2 Communication Services 2.08%
3 Industrials 0.52%
4 Technology 0.02%
5 Energy 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QURE icon
76
uniQure
QURE
$3.12B
$1.49M 0.13%
40,466
– –
AMRN
77
Amarin Corp
AMRN
$297M
$1.26M 0.11%
15,000
-11,250
-43% -$1.35M
ABEO icon
78
Abeona Therapeutics
ABEO
$423M
$944K 0.08%
37,000
– –
PVLA
79
Palvella Therapeutics
PVLA
$2.24B
$621K 0.06%
3,750
– –
QCOM icon
80
Qualcomm
QCOM
$171B
$280K 0.02%
2,381
– –
CVX icon
81
Chevron
CVX
$385B
$214K 0.02%
2,974
– –
F icon
82
Ford
F
$55.7B
$194K 0.02%
29,164
– –
BUD icon
83
AB InBev
BUD
$159B
– –
-2,806
Closed -$138K
DIS icon
84
Walt Disney
DIS
$179B
– –
-1,338
Closed -$149K
GEN icon
85
Gen Digital
GEN
$17.3B
– –
-6,926
Closed -$137K
HAL icon
86
Halliburton
HAL
$28.1B
– –
-8,299
Closed -$108K
IBM icon
87
IBM
IBM
$224B
– –
-1,660
Closed -$192K
JHG
88
DELISTED
Janus Henderson
JHG
– –
-8,645
Closed -$183K
JPM icon
89
JPMorgan Chase
JPM
$961B
– –
-1,723
Closed -$162K
OMCL icon
90
Omnicell
OMCL
$1.69B
– –
-60,000
Closed -$4.24M
PFE icon
91
Pfizer
PFE
$152B
– –
-4,751
Closed -$147K
WFC icon
92
Wells Fargo
WFC
$264B
– –
-5,272
Closed -$135K
XOM icon
93
ExxonMobil
XOM
$656B
– –
-5,388
Closed -$241K
AIMT
94
DELISTED
Aimmune Therapeutics
AIMT
– –
-285,000
Closed -$4.76M
MNTA
95
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
– –
-120,000
Closed -$3.99M
1 2 3
4

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return
BC
Brio Consultants San Francisco, California $818M AUM 13.48% 1-Year Est. Return

Rhenman & Partners Asset Management's Q3 2020 Portfolio in Review

As of Q3 2020, Rhenman & Partners Asset Management held 95 positions worth $1.12B, up 22% from $926M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Rhenman & Partners Asset Management deployed $144M of net new capital in Q3 2020, opening 1 new position and adding to 36 existing holdings. Its largest new stake was Accolade Inc: 151,674 shares worth $5.9M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Communication Services and Industrials.

On the sell side, the largest reduction was Immunomedics Inc, an estimated $12.1M trimmed.

  • Rhenman & Partners Asset Management's largest Q3 2020 buy was Accolade Inc: 151,674 shares worth $5.9M.
  • Rhenman & Partners Asset Management added most to BioMarin Pharmaceuticals in Q3 2020, an estimated $56.1M increase.
  • Rhenman & Partners Asset Management's biggest Q3 2020 reduction was Immunomedics Inc, cutting an estimated $12.1M.
  • Rhenman & Partners Asset Management fully exited Aimmune Therapeutics in Q3 2020, selling an estimated $4.76M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 31% of its $1.12B portfolio in Q3 2020.
  • Rhenman & Partners Asset Management opened 1 new position and closed 13 in Q3 2020.
  • Rhenman & Partners Asset Management's portfolio value rose 22% quarter-over-quarter to $1.12B.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2020, filed 13 Oct 2020.